Sangamo Therapeutics stock drops 23% on results of cutting-edge gene-editing trial
September 05, 2018 at 11:24 AM EDT
The trial marked the first instance of gene editing, or adding a new copy of a gene into the DNA of a patient’s cells, completed inside the body.
